Effects of trehalose on VEGF-stimulated angiogenesis and myofibroblast proliferation: implications for glaucoma filtration surgery

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 9, 2011, Pages 6987-6993

  Takeuchi, Kimio ^a   Nakazawa, Mitsuru ^a   Ebina, Yuichi ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; EYE DROPS; TREHALOSE; UVOMORULIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VIMENTIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELL STRUCTURE; CELL TRANSFORMATION; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MOUSE; MYOFIBROBLAST; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CELL TRANSDIFFERENTIATION; COCULTURE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; FILTERING OPERATION; GLAUCOMA; KERATITIS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); SKIN; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

ANIMALS; CELL PROLIFERATION; CELL TRANSDIFFERENTIATION; COCULTURE TECHNIQUES; CORNEAL NEOVASCULARIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FILTERING SURGERY; GLAUCOMA; HUMANS; KERATITIS; MICE; MICE, INBRED BALB C; MYOFIBROBLASTS; NEOVASCULARIZATION, PATHOLOGIC; SKIN; TREHALOSE; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VIMENTIN;

EID: 80054852825     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-7478     Document Type: Article

References (23)

1. Meyer-ter-Vehn T, Grehn F, Schlunck G. Localization of TGF-β type II receptor and ED-A fibronectin in normal conjunctiva and failed filtering blebs. Mol Vis. 2007;14:136-141.
2. Saika S. TGF-β pathobiology in the eye. Lab Invest. 2006;86:106-115.
3. Garrett Q, Khaw PT, Blalock TD, Schultz GS, Grotendorst GR, Daniels JT. Involvement of CTGF-in TGF-β1-stimulation of myofibroblast differentiation and collagen matrix constriction in the presence of mechanical stress. Invest Ophthalmol Vis Sci. 2004; 45:1109-1116.
4. Nagineni CN, Kutty V, Detrick B, Hooks JJ. Expression of PDGF and their receptors in human retinal pigment epithelial cells and fibroblasts: regulation by TGF-β. J Cell Physiol. 2005;203:35-43.
5. Andreev K, Zenkel M, Kruse F, Jünemann A, Schlötzer-Schrehardt U. Expression of bone morphogenetic proteins (BMPs), their receptors, and activins in normal and scarred conjunctiva: role of BMP-6 and activin-A in conjunctival scarring? Exp Eye Res. 2006; 83:1162-1170.
6. Wilgus TA, Ferreira AM, Oberyszyn TM, Bergdall VK, DiPietro LA. Regulation of scar formation by vascular endothelial growth factor. Lab Invest. 2006;88:579-590.
7. Diamond MP, El-Hammady E, Munkarah A, Bieber EJ, Saed G. Modulation of the expression of vascular endothelial growth factor in human fibroblasts. Fertil Steril. 2005;83:405-409.
8. Giatromanolaki A, Kotsiou S, Koukourakis M, Sivridis E. Angiogenic factor expression in hepatic cirrhosis. Mediat Inflamm. 2007;2007:Article ID 67187.
9. Abu El-Asrar A, Al-Kharashi SA, Missotten L, Geboses K. Expression of growth factors in the conjunctiva from patients with active trachoma. Eye. 2006;20:362-369.
10. Grewal DS, Jain R, Kumar H, Grewal SPS. Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy. Ophthalmology. 2008;115:2141-2145.
11. Memarzadeh F, Varma R, Lin L-T, et al. Postoperative use of bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit. Invest Ophthalmol Vis Sci. 2009;50:3233-3237.
12. Li Z, Van Bergen T, Van de Veire S, et al. Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2009;50:5217-5225.
13. How A, Chua JLL, Charlton A, et al. Combined treatment with bevacizumab and 5-fluorouracil attenuated the postoperative scarring response after experimental glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2010;51:928-932.
14. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijin EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004;56:549-580.
15. Wilgus TA, Ferreira AM, Oberyszyn TM, Bergdall VK, Dipietro LA. Regulation of scar formation by vascular endothelial growth factor. Lab Invest. 2008;88:579-590.
16. Bochmann F, Kaufmann C, Bechet CN, et al. ISRCTN12125882: influence of topical anti-VEGF (Ranibizumab) on the outcome of filtration surgery for glaucoma: study protocol. BMC Ophthalmol. 2011;11:1-23.
17. Takeuchi K, Nakazawa M, Ebina Y, et al. Inhibitory effects of trehalose on fibroblast proliferation and implications for ocular surgery. Exp Eye Res. 2010;91:567-577.
18. Matsuo T. Trehalose versus hyaluronan or cellulose in eyedrops for the treatment of dry eye. Jpn J Ophthalmol. 2004;48:321-327.
19. Nakamura T, Sekiyama E, Takaoka M, et al. The use of trehalosetreated freeze-dried amniotic membrane for ocular surface reconstruction. Biomaterials. 2008;29:3729-3737.
20. Greenfield DS, Parrish RK 2nd. Bleb rupture following filtering surgery with mitomycin-C: clinicopathologic correlations. Ophthalmic Surg Lasers. 1996;27:876-877.
21. DeBry PW, Perkins TW, Heatley G, Kaufman P, Brumback LC. Incidence of late-onset bleb-related complications following trabeculectomy with mitomycin. Arch Ophthalmol. 2002;120:297-300.
22. CAT-1520102 Trabeculectomy Study Group, Khaw P, Grehn F, et al. A phase III study of subconjunctival human anti-transforming growth factor beta(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmology. 2007; 114:1822-1830.
23. Hersley MB, Kahook MY. Anti-VEGF therapy for glaucoma. Curr Opin Ophthalmol. 2010;21:112-117.